8-K current report · filed Oct 22, 2026

Disc Medicine, Inc. (IRON) 8-K Current Report: October 22, 2026

Item 1.01Item 8.01Item EX-99.1Item EX-99.2Item 2.02IRON overview

Short answer

Disc Medicine, Inc. (IRON) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). $450.0 million gross equity offering: 6,000,000 shares at $75.00 each, completed October 22, 2026.

Disc Medicine, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $450.0 million gross equity offering: 6,000,000 shares at $75.00 each, completed October 22, 2026
  • Potential additional 900,000 shares through underwriters’ 30-day option, increasing gross proceeds by $67.5 million
  • Net proceeds approximately $422.4 million, or $485.9 million with full option exercise
  • Funding runway extended into 2030 for operations, capital expenditures and debt service, excluding bitopertin or other product revenue
  • Equity issuance creates shareholder dilution but materially reduces near-term financing risk

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary cash, cash equivalents and marketable securities of approximately $682.8 million as of September 30, 2026
  • Liquidity estimate offers investors visibility into near-term funding capacity
  • Unaudited figure remains subject to change after quarter-end close and Form 10-Q filing

Item 8.01 · Other Events

  • Equity offering commenced October 19, 2026, signaling near-term capital raising for operations and development
  • Offering priced October 20, 2026, with terms and proceeds detailed in Exhibits 99.1 and 99.2
  • Expected net proceeds and cash runway are key investor implications, but remain forward-looking estimates
  • Financing addresses capital needs for clinical trials, pipeline expansion, and potential regulatory activities
  • Dilution and runway impact require review of the attached offering terms

Item EX-99.1 · Exhibit EX-99.1

  • Proposed $350 million underwritten equity offering, signaling substantial funding for Disc Medicine’s development pipeline
  • Underwriters’ 30-day option for an additional $52.5 million, potentially increasing total gross proceeds
  • Proceeds targeted toward bitopertin commercialization, clinical research, pre-commercialization, and working capital
  • Common shares and pre-funded warrants create potential shareholder dilution
  • Offering remains subject to market conditions and may not close on proposed terms or at all

Item EX-99.2 · Exhibit EX-99.2

  • $450 million gross equity raise at $75.00 per share, strengthening funding for clinical development and commercialization
  • 6,000,000 new shares create dilution for existing shareholders
  • Underwriters hold a 30-day option for 900,000 additional shares, increasing potential dilution
  • Proceeds support potential bitopertin commercialization in EPP and XLP, plus other pipeline programs
  • Closing expected October 22, 2026, subject to customary conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Disc Medicine, Inc. 8-K filings

Get the next IRON 8-K as it lands

Follow IRON for push alerts, or ask the research agent what this filing means.